~~<i id='6C9F70FCB7'><strike id='6C9F70FCB7'><tt id='6C9F70FCB7'><pre id='6C9F70FCB7'></pre></tt></strike></i>~~

Home» knowledge» Wikipedia

Wikipedia

author：comprehensive 2025-09-28 10:07:45 Page View：463

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Popular nasal decongestant doesn't actually relieve congestion
Next article： Wildfire smoke exposes gaps in outdoor worker protections

knowledge

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

FDA proposes changes to key medical devices approval pathway

Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

New weight loss drugs vying to be the next Wegovy or Mounjaro

MollyFergusonforSTATTheexplodingpopularityofdrugslikeWegovyandMounjarohaspropelleddozensofcompaniest